Next Article in Journal
Health Literacy and Clinical Trial Participation in French Cancer Patients: A National Survey
Next Article in Special Issue
Routine Screening for Central and Primary Adrenal Insufficiency during Immune-Checkpoint Inhibitor Therapy: An Endocrinology Perspective for Oncologists
Previous Article in Journal
Patient-Reported Outcomes Measurement in Radiation Oncology: Interpretation of Individual Scores and Change over Time in Clinical Practice
Previous Article in Special Issue
Immune Checkpoint Inhibitors in Cancer Therapy
 
 
Article

Real-World Adherence to Toxicity Management Guidelines for Immune-Related Adverse Events

1
Department of Pharmacy, Nova Scotia Health, QEII Health Sciences Centre, Halifax, NS B3H 3A7, Canada
2
QEII Health Sciences Centre, Division of Medical Oncology, Dalhousie University, Halifax, NS B3H 4R2, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2022, 29(5), 3104-3117; https://doi.org/10.3390/curroncol29050252
Received: 1 April 2022 / Revised: 22 April 2022 / Accepted: 26 April 2022 / Published: 28 April 2022
Immune checkpoint inhibitors (ICIs) affect immunologic homeostasis, leading to immune-related adverse events (irAEs). Early irAE detection and management can prevent significant morbidity and mortality. A retrospective chart review was performed to characterize irAEs associated with nivolumab, ipilimumab, and nivolumab plus ipilimumab in adult medical oncology patients in Nova Scotia Health-Central Zone from 2013–2020, and to describe adherence to toxicity management guidelines. Diarrhea/colitis, hepatitis, pneumonitis, nephrotoxicity, and cardiotoxicity were studied. Of 129 charts reviewed, 67 patients (51.9%) experienced at least one irAE for a total of 98 irAEs and a 1.5% fatality rate. Of these irAEs, 33.7% led to an emergency room visit. Patients were admitted to hospital and steroids were used in 24.5% and 35.7% of cases, respectively. In 17.3% of irAEs, ICIs were permanently discontinued. In 20.4% of irAEs, ICIs were held, and patients were monitored; while in 18.4%, ICIs were held until the irAE was Grade 0–1 (and until steroids were tapered). Almost 47% of irAEs were managed according to guidelines (14.3% were not), and 38.8% had no documented management. Patients receiving immunotherapy frequently experience irAEs with half of irAEs having documented management adhering to guidelines. As immunotherapy indications expand, it is important to ensure irAEs are documented and managed appropriately. View Full-Text
Keywords: immune-related adverse events; immune checkpoint inhibitors; quality assurance; toxicity guideline adherence immune-related adverse events; immune checkpoint inhibitors; quality assurance; toxicity guideline adherence
Show Figures

Figure 1

MDPI and ACS Style

Teimouri, A.; Minard, L.V.; Scott, S.N.; Daniels, A.; Snow, S. Real-World Adherence to Toxicity Management Guidelines for Immune-Related Adverse Events. Curr. Oncol. 2022, 29, 3104-3117. https://doi.org/10.3390/curroncol29050252

AMA Style

Teimouri A, Minard LV, Scott SN, Daniels A, Snow S. Real-World Adherence to Toxicity Management Guidelines for Immune-Related Adverse Events. Current Oncology. 2022; 29(5):3104-3117. https://doi.org/10.3390/curroncol29050252

Chicago/Turabian Style

Teimouri, Arezou, Laura V. Minard, Samantha N. Scott, Amanda Daniels, and Stephanie Snow. 2022. "Real-World Adherence to Toxicity Management Guidelines for Immune-Related Adverse Events" Current Oncology 29, no. 5: 3104-3117. https://doi.org/10.3390/curroncol29050252

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop